Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: Pharmacokinetics and short-term safety

Pediatric Research

Volumn 73, Issue 1, 2013, Pages 68-74

  Ley, David ^a   Hansen Pupp, Ingrid ^a   Niklasson, Aimon ^b   Domellöf, Magnus ^c   Friberg, Lena E ^d   Borg, Jan ^e   Löfqvist, Chatarina ^f   Hellgren, Gunnel ^b   Smith, Lois E H ^g   Hård, Anna Lena ^f   Hellström, Ann ^f  

^a LUND UNIVERSITY   (Sweden)

^b SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e Uppsala Science Park   (Sweden)

^f UNIVERSITY OF GOTHENBURG   (Sweden)

^g BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREMIPLEX; RECOMBINANT SOMATOMEDIN C; RECOMBINANT SOMATOMEDIN C PLUS RECOMBINANT SOMATOMEDIN BINDING PROTEIN 3; RINFABATE; UNCLASSIFIED DRUG;

ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; GESTATION PERIOD; GESTATIONAL AGE; HUMAN; HYPOGLYCEMIA; MALE; NEWBORN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETROLENTAL FIBROPLASIA; TREATMENT DURATION;

BRAIN; FEMALE; HUMANS; INFANT, EXTREMELY PREMATURE; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; RETINOPATHY OF PREMATURITY; SWEDEN;

EID: 84872069596     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2012.146     Document Type: Article

References (32)

1. Gluckman PD. Clinical review 68: the endocrine regulation of fetal growth in late gestation: the role of insulin-like growth factors. J Clin Endocrinol Metab 1995;80:1047-50.
2. Netchine I, Azzi S, Le Bouc Y, Savage MO. IGF1 molecular anomalies demonstrate its critical role in fetal, postnatal growth and brain development. Best Pract Res Clin Endocrinol Metab 2011;25:181-90.
3. Ashton IK, Zapf J, Einschenk I, MacKenzie IZ. Insulin-like growth factors (IGF) 1 and 2 in human foetal plasma and relationship to gestational age and foetal size during midpregnancy. Acta Endocrinol 1985;110:558-63.
4. Lassarre C, Hardouin S, Daffos F, Forestier F, Frankenne F, Binoux M. Serum insulin-like growth factors and insulin-like growth factor binding proteins in the human fetus. Relationships with growth in normal subjects and in subjects with intrauterine growth retardation. Pediatr Res 1991;29:219-25.
5. Hansen-Pupp I, Hellstr-Westas L, Cilio CM, Andersson S, Fellman V, Ley D. Inflammation at birth and the insulin-like growth factor system in very preterm infants. Acta Paediatr 2007;96:830-6.
6. Langford K, Nicolaides K, Miell JP. Maternal and fetal insulin-like growth factors and their binding proteins in the second and third trimesters of human pregnancy. Hum Reprod 1998;13:1389-93.
7. Hellstr A, Engstr E, Hard AL, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003;112:1016-20.
8. Leqvist C, Engstr E, Sigurdsson J, et al. Postnatal head growth deficit among premature infants parallels retinopathy of prematurity and insulinlike growth factor-1 deficit. Pediatrics 2006;117:1930-8.
9. Holly J, Perks C. The role of insulin-like growth factor binding proteins. Neuroendocrinology 2006;83:154-60.
10. Lofqvist C, Chen J, Connor KM, et al. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci USA 2007;104:10589-94.
11. Hansen-Pupp I, Engstr E, Niklasson A, et al. Fresh-frozen plasma as a source of exogenous insulin-like growth factor-I in the extremely preterm infant. J Clin Endocrinol Metab 2009;94:477-82.
12. Leqvist C, Niklasson A, Engstr E, et al. A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. Pediatr Res 2009;65:574-9.
13. Mizuno N, Kato Y, Iwamoto M, et al. Kinetic analysis of the disposition of insulin-like growth factor 1 in healthy volunteers. Pharm Res 2001;18:1203-9.
14. Guler HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol 1989;121:753-8.
15. Grahn A, Kastrup K, Heinrich U, et al. Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency. Acta Paediatr Suppl 1993;82:suppl 391:9-13; discussion 14.
16. Camacho-Hner C, Rose S, Preece MA, et al. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. J Clin Endocrinol Metab 2006;91:1246-53.
17. Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL, et al. A randomised controlled trial of early insulin therapy in very low birth weight infants, "NIRTURE" (neonatal insulin replacement therapy in Europe). BMC Pediatr 2007;7:29.
18. Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT. The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol 2001;170:63-70.
19. Lewitt MS, Scott FP, Clarke NM, Baxter RC. Developmental regulation of circulating insulin-like growth factor-binding proteins in normal pregnancies and in pre-eclampsia. Prog Growth Factor Res 1995;6:475-80.
20. Herndon DN, Ramzy PI, DebRoy MA, et al. Muscle protein catabolism after severe burn: effects of IGF-1/IGFBP-3 treatment. Ann Surg 1999;229:713-20; discussion 720-2.
21. Beardsall K, Ogilvy-Stuart AL, Frystyk J, et al. Early elective insulin therapy can reduce hyperglycemia and increase insulin-like growth factor-I levels in very low birth weight infants. J Pediatr 2007;151:611-7, 617. e1.
22. Hikino S, Ihara K, Yamamoto J, et al. Physical growth and retinopathy in preterm infants: involvement of IGF-I and GH. Pediatr Res 2001;50:732-6.
23. Hansen-Pupp I, Leqvist C, Polberger S, et al. Influence of insulin-like growth factor I and nutrition during phases of postnatal growth in very preterm infants. Pediatr Res 2011;69(5 Pt 1):448-53.
24. Fryburg DA, Jahn LA, Hill SA, Oliveras DM, Barrett EJ. Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. J Clin Invest 1995;96:1722-9.
25. Kaempf JW, Kaempf AJ, Wu Y, Stawarz M, Niemeyer J, Grunkemeier G. Hyperglycemia, insulin and slower growth velocity may increase the risk of retinopathy of prematurity. J Perinatol 2011;31:251-7.
26. Hansen-Pupp I, Hael H, Hellstr A, et al. Postnatal decrease in circulating insulin-like growth factor-I and low brain volumes in very preterm infants. J Clin Endocrinol Metab 2011;96:1129-35.
27. Vanhaesebrouck S, Danis H, Moons L, Vanhole C, Carmeliet P, De Zegher F. Oxygen-induced retinopathy in mice: amplification by neonatal IGF-I deficit and attenuation by IGF-I administration. Pediatr Res 2009;65:307-10.
28. Mars K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr 1996;85:843-8.
29. Niklasson A, Albertsson-Wikland K. Continuous growth reference from 24th week of gestation to 24 months by gender. BMC Pediatr 2008;8:8.
30. Blum WF, Breier BH. Radioimmunoassays for IGFs and IGFBPs. Growth Regul 1994;4:Suppl 1:11-9.
31. Beal S, Sheiner LB, Boeckmann, AJ. 1989-2006 NONMEM Users Guides. Ellicott City, Maryland: Icon Development Solutions, 1989-2006.
32. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008;48: 303-32.